PCIB.OL

PCI Biotech Holding ASA [PCIB.OL] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?

PCIB.OL Stock Summary

An RSI reading of 30 or below indicates an oversold or undervalued condition.

In the News

PCIB.OL Financial details

Company Rating

Market Cap

66.44M

Income

-26.14M

Revenue

Book val./share

Cash/share

Dividend

Dividend %

Employees

Optionable

Shortable

Yes

Earnings

10 May 2024

P/E

-3.03

Forward P/E

PEG

0.59

P/S

P/B

1.81

P/C

P/FCF

-2.51

Quick Ratio

8.49

Current Ratio

9.69

Debt / Equity

LT Debt / Equity

EPS (TTM)

-0.7

EPS next Y

EPS next Q

EPS this Y

-62.5%

EPS next Y

EPS next 5Y

EPS last 5Y

Revenue last 5Y

Revenue Q/Q

EPS Q/Q

53.33%

SMA20

-26.32%

SMA50

-30%

SMA100

-48.15%

Inst Own

Inst Trans

ROA

-53%

ROE

-51%

ROC

-0.65%

Gross Margin

Oper. Margin

Profit Margin

Payout

Shs Outstand

Shs Float

Target Price

52W Range

1.2-3.4

52W High

-97.67%

52W Low

-93%

RSI

26.45

Rel Volume

18.46

Avg Volume

90.31K

Volume

1.67M

Perf Week

-55.84%

Perf Month

-75.78%

Perf Quarter

Perf Half Y

-75%

Beta

1.615

Volatility

0.03%, 0.04%

Prev Close

-39.13%

Price

0.07

Change

-46.56%

Something similar

Top by Market Cap

Same Sector

Same Price Range

Similar Market Cap

Company Profile

Volume Average 90.31K
Market Capitalization 66.44M
Employee 6
CEO Mr. Ronny Skuggedal
Headquarters Oslo,NO
IPO Date 2008-06-23
Website https://www.pcibiotech.com

PCI Biotech Holding ASA, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for the treatment of cancer through its photochemical internalization (PCI) technology platform. The company develops anticancer paradigms, including fimaCHEM, a chemotherapeutics for treatment of cancer; fimaVACC, a T-cell induction technology for therapeutic vaccination, which is in Phase I clinical study; and fimaNAc, a nucleic acid therapeutics delivery technology, which is in pre-clinical study. It also offers Amphinex, a photosensitiser fimaporfin. The company has collaborative research programs with Bavarian Nordic, BioNTech, Phio Pharmaceuticals, DCprime, eTheRNA immunotherapies, IMV, and Aposense. PCI Biotech Holding ASA is based in Oslo, Norway.